Rosuvastatin, sildenafil and their combination in monocrotaline-induced pulmonary hypertension in rat by MAGDALENA JASIŃSKA-STROSCHEIN et al.
345
Acta Pharm. 64 (2014) 345–354 Original research paper
DOI: 10.2478/acph-2014-0029
Rosuvastatin, sildenafil and their combination in monocrotaline-
-induced pulmonary hypertension in rat
There is considerable interest in the pleiotropic effects of 
statins and their potential role in the treatment of pulmo-
nary hypertension. Previous experimental findings indi-
cate that a combination of lipophilic statins with phospho-
diesterase type-5 inhibitor, sildenafil, can offer preventive 
effects on rat monocrotaline-induced pulmonary hyperten-
sion. The present study is aimed to assess whether thera-
peutic regimen provides any benefits. Seven days after pul-
monary hypertension induction, hydrophilic rosuvastatin 
and sildenafil were given for 14 days to male Wistar out-
bred rats. Right ventricular pressure, right ventricle mass 
and three biomarkers were evaluated after 21 days: brain 
natriuretic peptide, high-density lipoprotein cholesterol 
and vascular endothelial growth factor. The present study 
demonstrates that administration of hydrophilic statin 
with sildenafil results in reduction of pulmonary vascular 
remodeling and right ventricular pressure. The results of 
biochemical measurements may suggest that statins play a 
positive role in right ventricle function or the process of 
angiogenesis in pulmonary hypertension development.
Keywords: rosuvastatin, sildenafil, combination therapy, 
pulmonary hypertension, hemodynamic parameters
HMG-CoA reductase inhibitors (statins) are well-known for their pleiotropic effects 
which go beyond serum cholesterol lowering activity (1, 2). It has been demonstrated that 
statins might offer preventive or therapeutic benefits in animal models of pulmonary hy-
pertension (PH) (3, 4). Such effects, primarily concerned with improving or restoring en-
dothelial function, inhibiting the proliferation and migration of vascular smooth muscle 
cells or reducing myocardial mass and fibrosis (5), have been demonstrated mainly for 
simvastatin, one of the most »popular« statins, with pleiotropic activity being confirmed 
clinically in a number of multicenter trials (6). The influence of other statins, including less 
lipophilic ones, has only been assessed in very few experimental studies (7–10). Satoh et al. 
(7) did not observe 28-d pravastatin administration to have any significant impact on the 
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crotaline (MCT) rat model. In opposite, Sun et al. (8) showed that another hydrophilic statin 
– rosuvastatin when given especially for early protection against PH development had 
positive impact on myocardial hypertrophy and reduction of pulmonary pressure. Also, 
the benefits of adding statins to a conventional regimen have been investigated in several 
studies. These have usually included lipophilic statins, such as simvastatin or atorvastatin, 
and the drugs were administered just after induction of pulmonary hypertension as a 
preventive regimen. The results of such previous studies vary. Kuang et al. (11) showed 
sildenafil to have further benefits in a preventive model if co-administered with simvas-
tatin. Zhao et al. (12) confirmed the beneficial impact of therapeutic regimen of statin on 
further reduction in right ventricle hypertrophy (RVH) and vascular remodeling when 
added to sildenafil therapy. However, the obtained results were not accompanied by fur-
ther reduction of pulmonary arterial pressure (PAP) as compared to sildenafil alone (12). 
Other studies have not demonstrated any such hemodynamic benefits when statin was 
added to conventional – sildenafil (13) or beraprost (7) therapy. Based on these reports, the 
present study was undertaken to assess whether hydrophilic HMG-CoA reductase in-
hibitor could provide greater effects if added to a conventional PH regimen. A MCT rat 
model was used to evaluate the effects of the combined usage of rosuvastain with sildena-
fil, an agent known to be effective in reducing pulmonary hypertension. The study was 
addressed to therapeutic not preventive regimen, i.e., drugs were administered after pul-
monary hypertension development. The effects of such treatment were assessed in relation 
to the normalization of RVP and to the right ventricle mass, especially. The study includes 
some circulating markers regarded as being associated with PH, as several are known to 
have prognostic potential and show promise for monitoring the response to PH therapy. 
These are high-density lipoprotein cholesterol (HDL-C), brain natriuretic peptide (BNP) 
and vascular endothelial growth factor A (VEGF-A).
EXPERIMENTAL
Animals
The experiments were performed on thirty-eight outbred Wistar male rats, body mass 
230–400 g, fed on granulated Murigran (Agropol S. J., Poland), with free access to water. 
The animals were housed in standard cages, five animals per cage. The experimental pro-
cedures were carried out in accordance with the international guidelines for care and use 
of laboratory animals. All efforts were made to minimize animal suffering and reduce the 
number of animals used in the experiments. All the procedures in these experiments were 
approved by the Ethics Committee of the Medical University of Lodz, Poland.
All drugs, in doses detailed in previous experiments on rats (14, 15), were adminis-
tered by oral gavage, intragastrically (i.g.) suspended in 1.0 % methylcellulose (MC).
Monocrotaline treatment. – Monocrotaline (MCT, Fluorochem Ltd, UK) was dissolved 
in 1 mol L–1 HCl, and pH was adjusted to 7.4 with 1 mol L–1 NaOH (15). Monocrotaline was 
administered as a single, subcutaneous (s.c.) injection (60 mg kg–1) in a volume of 3 mL kg–1. 
Control, age-match ed rats received an equal volume of vehicle.
347
M. Jasińska-Stroschein et al.: Rosuvastatin, sildenafil and their combination in monocrotaline-induced pulmonary hypertension in 
rat, Acta Pharm. 64 (2014) 345–354.
 
Experimental design. – The animals were divided into five groups of rats, randomly 
allocated to each group: 1) healthy rats receiving 1.0 % methylcellulose, 1 mL kg–1, i.g. daily 
for 14 days (n = 9) – control group; 2) monocrotaline-induced rats receiving 1.0 % methylcel-
lulose, 1 mL kg–1, i.g. daily for 14 days after single, subcutaneous monocrotaline injection 
– MCT (n = 8); 3) monocrotaline-induced rats receiving rosuvastatin 10 mg kg–1, i.g. daily 
for 14 days (n = 8) – MCT+ROS; 4) monocrotaline-induced rats receiving sildenafil 25 mg kg–1 
i.g. daily for 14 days (n = 6) – MCT+SIL; 5) monocrotaline-induced rats receiving rosuvasta-
tin 10 mg/kg + sildenafil 25 mg kg–1, i.g. daily for 14 days (n = 7) – MCT+ROS+SIL. Rats were 
weighed once a week. The first dose of drug in the following group of animals: MCT+ROS, 
MCT+SIL, MCT+ROS+SIL was given 7 days after MCT injection.
Hemodynamic studies. – The surgery was performed 24 hours after the administration 
of the last drug dose. The rats were placed in dorsal position on the operation table. The 
animals were anaesthetized with penthobarbital sodium (30 mg kg–1), administered intra-
peritoneally. Anesthesia was maintained by additional bolus doses of penthobarbital so-
dium as needed. Lidocaine was used for local infiltration of the surgical sites. The registra-
tion of hemodynamic parameters in rats was performed by using a Hugo Sachs Electronik 
Haemodyn (Harvard Apparatus GmbH, Germany), as described previously (16).
Measurement of organ mass. – At the end of the study, after animal euthanasia, the heart 
was excised. Next, the right ventricle, right atrium and left ventricle plus septum were 
separated and weighed. The ratio of the right ventricle weight to left ventricle plus septum 
weight (RV/LV+S) as a index of right ventricular hypertrophy was calculated.
Measurement of HDL-C, VEGF-A and BNP levels. – The levels of BNP and VEGF-A were 
measured in plasma samples with commercially available ELISA kits for rats (Life Science 
Inc., USA) and HDL-C  was measured in plasma samples with reagents provided by Bio-
labo Reagents, France.
Statistical analysis
The statistical analysis was carried out using the Statgraphics Plus 5.0. The statistical 
evaluation was performed using the analysis of variance (ANOVA) and post-hoc com-
parisons were performed using the Student-Newman-Keuls test. Normal distribution of a 
parameter was checked by means of the Kolmogorov-Smirnov test with the Lillieforce 
correction. The homogeneity of variance was tested by Levene’s test. All parameters were 
considered statistically significantly different if p < 0.05.
RESULTS AND DISCUSSION
Survival and hemodynamic parameters and cardiac hypertrophy
At the end of the study, no rats died in the control as well as monocrotaline and other 
experimental groups.
A single subcutaneous injection of MCT resulted in significant increase in right ven-
tricular pressure (RVP) compared to saline injected control animals (p < 0.05). The 14-day 
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Fig. 1. Right ventricular pressure (RVP) and right ventricular hypertrophy expressed as the ratio of 
the right ventricular mass to left ventricle plus septum mass (RV/LV+S) in the following groups of 
rats: control; monocrotaline – MCT; sildenafil – MCT+SIL; rosuvastatin – MCT+ROS; rosuvastatin + 
sildenafil – MCT+ROS+SIL. Results expressed as mean ± SE, n = 38. Significant difference: * p < 0.05 as 
compared to monocrotaline (MCT) group, ** p < 0.05 as compared to rosuvastatin group, † p < 0.05 as 
compared to control group.
administration of sildenafil at the dose of 25 mg kg–1  or rosuvastatin at the dose of 10 mg 
kg–1 reduced RVP significantly compared to MCT treated animals (p < 0.05). Fourteen-day 
administration combined administration of rosuvastatin and sildenafil caused significant 
decrease in RVP parameter compared to monocrotaline (p < 0.05) and to rosuvastatin alone 
(p < 0.05) (Fig. 1).
No significant difference regarding values of heart rate, systolic, mean and diastolic 
blood pressure among examined groups of animals was noted.
The ratio of the right ventricle mass to left ventricle plus septum mass (RV/LV+S) was 
significantly higher in MCT treated animals than in control group (p < 0.05). The adminis-
tration of sildenafil alone caused significant decrease of this ratio (p < 0.05). Also, combined 
administration of sildenafil and rosuvastatin resulted in significant decrease in RV/LV+S 
ratio compared to MCT rats (p < 0.05) and to rosuvastatin alone (p < 0.05) (Fig. 1).
Biochemical parameters
Administration of rosuvastatin and sildenafil alone or in combination did not cause 
any significant changes in plasma HDL-C level compared to MCT treated rats or saline 
group (Fig. 2).
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In monocrotaline treated rats plasma VEGF-A level was significantly lower compared 
to saline control group (p < 0.05). Administration of rosuvastatin or sildenafil alone caused 
a significant increase in plasma VEGF-A compared to MCT treated rats (p < 0.05). Com-
bined, sildenafil plus rosuvastatin, administration caused increase in VEGF-A level com-
pared to rats exposed to MCT (p = 0.0502) (Fig. 2).
Monocrotaline induction caused significant increase in plasma BNP level compared 
to saline control group (p < 0.05). Administration of rosuvastatin or sildenafil alone caused 
Fig. 2. Plasma HDL-C, VEGF-A and BNP levels in groups of rats: control, monocrotaline – MCT, 
sildenafil – MCT+SIL, rosuvastatin – MCT+ROS, rosuvastatin + sildenafil – MCT+ROS+SIL. Results 
expressed as mean ± SE, n = 38. Significant difference: * p < 0.05 as compared to monocrotaline (MCT) 
group, † p < 0.05 as compared to control group.
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a significant decrease in plasma BNP level compared to MCT treated rats (p < 0.05); the 
same is true for combined sildenafil and rosuvastatin administration (Fig. 2).
The current approach to the treatment of pulmonary hypertension is to combine 
drugs from different classes to achieve greater therapeutic effects (17). This study is the 
first to present the »added« effects of a therapeutic regimen of hydrophilic rosuvastatin 
co-administered with sildenafil, agent with confirmed efficacy in PH, as opposed to a pre-
ventive one. In the present study each drug significantly reversed a MCT-induced increase 
in RVP, however, their combined usage brought beneficial therapeutic but not additive 
results. In the study hydrophilic rosuvastatin was found to have moderate but significant 
effects, as similarly noted by Pei et al. (9). These authors observed rosuvasta tin-induced 
modulation of right ventricular function, normalization of right ventricular hypertrophy 
as well as remodeling the small pulmonary artery; these effects were mediated through 
regulating the protein kinase Akt and endothelial nitric oxide synthase (Akt/eNOS) signal-
ing pathway. As mentioned above, previous experimental research showed sildenafil to 
have further benefits in a preventive model if co-administered with simvastatin (11). Sim-
vastatin and sildenafil are both substrates for the CYP3A4 isoenzyme. The potential com-
petitive inhibition of drug metabolism might explain the further enhancement of sildena-
fil activity in a study by Kuang et al. (11). The opportunity of greater exposure being offered 
by a combination of sildenafil and simvastatin was also discussed by authors of clinical 
trial (SIPTH) (18). However, although such a mechanistic explanation could be attributed 
to sildenafil-simvastatin, the same cannot be said for the sildenafil-rosuvastatin interac-
tion. In contrast to the lipophilic simvastatin (19), the hydrophilic rosuvastatin is a poor 
substrate of CYP3A4 without inhibitory activity towards cytochrome P450 isoenzymes. 
Nevertheless, recent clinical trials demonstrate only transient efficacy when phosphodies-
terase type 5 inhibitor and/or endothelin receptor antagonist were supplemented by statins 
in PH (18). Such disappointing results have raised i.e., the question of whether particular 
statins at particular doses or regimens will be effective rather than all statins (18, 20). The 
time when statin is added to PH conventional therapy might also influence its efficacy. 
Although the findings of the present study, and those of earlier studies, imply that co-ad-
ministration of statin with conventional drugs could confer advantages in treating PH, 
especially for its early protection, further studies are needed to confirm this.
The results of the present study also indicate that rosuvastatin therapy, administered 
as monotherapy or in combination with sildenafil, exerts a significant impact on the chang-
es of several factors which act as prognostic biomarkers in PH. Although this is confirmed 
for BNP, it is only discussed for VEGF-A. The role of such factors in pulmonary hyperten-
sion, together with several mechanistic implications, has been previously discussed (16).
The present study is first to demonstrate that a therapeutic statin regimen exerts a 
beneficial impact on reduction of BNP levels being elevated in MCT-induced PH. The ben-
efits of statin therapy on right ventricle function with BNP level reductions have been 
described in heart failure or myocardial infarction (21, 22). Our observations suggest that 
statins might also play a positive role by ameliorating increased wall stress in the right 
ventricle in pulmonary hypertension. Very little data is available regarding statin impact 
on angiogenesis with VEGF changes resulting in pulmonary hypertension development. 
Chen et al. (23) observed that VEGF mRNA expression levels were increased in the lungs 
of a dehydromonocrotaline group, and these increases were reduced towards normal lev-
els in the statin-treated group. However, our findings show that plasma VEGF levels were 
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significantly higher in treated and saline control groups as compared to the monocrotaline 
group, and these observations were similar to the results of other treatment regimens 
(bosentan, sildenafil or iloprost) as described by Yigitaslan et al. (24). The authors con-
cluded that lower serum and pulmonary artery VEGF levels in MCT group compared to 
treated ones may suggest the protective function of VEGF in early PH phases. However, 
further studies to evaluate the precise mechanistic linkage are needed.
There are some limitations of the study. First, mean pulmonary arterial pressure or 
cardiac output were not assessed. As previous experiments on PH animal models show, 
drug-induced alterations in RVP tend to reflect changes of pulmonary artery hemodynam-
ics (11, 25). Secondly, the effects on pulmonary vessels could demonstrate the antiremodel-
ing properties of proposed regimens, in addition to the hemodynamics and right ventricle 
hypertrophy results.
CONCLUSIONS
In conclusion, the present preliminary study shows that therapeutic regimen of a 
hydrophilic statin, rosuvastatin, can reverse MCT-induced pulmonary hypertension in 
rats in a moderate, but significant, manner by reducing pulmonary vascular remodeling 
and right ventricular pressure.
The results of biochemical measurements may suggest that statin plays a positive role 
towards right ventricle function or angiogenesis process in PH development. However, no 
additive effect of combination therapy with sildenafil was demonstrated. Further studies 
are needed to assess statin benefits in pulmonary hypertension in relation to the impact of 
study regimen (i.e., therapeutic vs. preventive), the potential effects of other drug-statin 
interactions and their mechanistic background.
Acronyms. BNP – brain natriuretic peptide, eNOS – endothelial nitric oxide synthase, HDL-C – 
high-density lipoprotein cholesterol, MC – methylcellulose, MCT – monocrotaline, PH – pulmonary 
hypertension, PAP – pulmonary arterial pressure, ROS – rosuvastatin, RVH – right ventricle hyper-
trophy, RV/LV+S – ratio of the right ventricle mass to left ventricle plus septum mass, RVP – right 
ventricular pressure, SIL – sildenafil, VEGF – vascular endothelial growth factor
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